| HOME >> MEDICINE >> TECHNOLOGY |
Figure 2: The Drug-Target Competitive Landscape of Lymphoma Drugs - Large Clusters 331
Figure 3: The Drug-Target Competitive Landscape Lymphoma Drugs - Smaller Clusters 332
Figure 4: Head-to-Head Targeting Competitive Landscape of Lymphoma Drugs 333
Figure 5: Distribution of Compound Strategies among Lymphoma Drugs 631
Figure 6: Primary Sub-cellular Localization of Drug Targets 632
4.2 List of Tables
Table 1: Cancer Highlights'™ Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Lymphoma Drug Pipeline by Stage of Development 26
Table 3: Head to Head Target Competition among Lymphoma Drugs 26
Table 4: Overview of Drug Target Strategy Themes 31
Table 5: Terminally Ceased Targets of Lymphoma Drugs 32
Table 6: Official Gene Name to Target Profle 32
Table 7: Targets of Lymphoma Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 316
Table 8: Identity of Lymphoma Drug Targets with Available Biological Structures 321
Table 9: Number of Target-Target Interactions among Targets of Lymphoma Drugs 325
Table 10: Available Protein Expression Profiles of Lymphoma Drugs Targets 334
Table 11: Pathway Summary 340
Table 12: Drug Targets without any Identified Assigned Pathways 340
Table 13: Pathway Profiles According to BioCarta of Lymphoma Drug Targets 342
Table 14: Pathway Profiles According to KEGG of Lymphoma Drug Targets 361
Table 15: Pathway Profiles According to NetPath of Lymphoma Drug Targets 383
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 388
Table 17: Top Competitive Target Strategies of Lymphoma Drugs 389
Table 18: New and Unique Target Strategies of Pre-registration and Marketed Lymphoma Drugs 392
Table 19: The Competition Through Close Mechanistic Approximation Bet
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |